Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanine SCHEMBL31714144 | 1.00 | BRAF (0.38) | BRAFPDPK1GDACDK2DPP4 | |
| SCHEMBL2938904 | 0.81 | BRAF (0.36) | BRAFPDPK1GDACDK2DPP4 | |
| Xanthine SCHEMBL918381 | 0.79 | MEN1 (0.34) | ALDH1A1LMNAMEN1POLBKMT2A | |
| Xanthine SCHEMBL9443796 | 0.79 | MEN1 (0.34) | ALDH1A1LMNAMEN1POLBKMT2A | |
| 2,6-Diaminopurine SCHEMBL29444619 | 0.79 | GDA (0.48) | PDPK1GDACDK2DPP4ALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL24052 | 0.79 | GDA (0.48) | PDPK1GDACDK2DPP4ALDH1A1 | |
| SCHEMBL8485064 | 0.78 | PDPK1 (0.36) | BRAFPDPK1GDACDK2DPP4 | |
| 2,6-Diaminopurine SCHEMBL6423146 | 0.78 | GDA (0.47) | PDPK1GDACDK2DPP4ALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL8757968 | 0.78 | GDA (0.47) | PDPK1GDACDK2DPP4ALDH1A1 | |
| SCHEMBL20093433 | 0.77 | CDK2 (0.37) | BRAFPDPK1GDACDK2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | claimed |
| CN-115433361-A | Polyphosphazene derivative flame retardant for toughening flame-retardant polylactic acid and preparation method thereof | 浙江农林大学 | 2022-12-06 | — | — | CN | claimed |
| CN-113089037-B | Electroplating solution for electroplated diamond wire saw and preparation method thereof | 广州三孚新材料科技股份有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-110408968-B | Chemical plating solution and preparation method and application thereof | 中国科学院深圳先进技术研究院 | 2021-11-05 | — | — | CN | claimed |
| CN-113089037-A | Electroplating solution for electroplated diamond wire saw and preparation method thereof | 广州三孚新材料科技股份有限公司 | 2021-07-09 | — | — | CN | claimed |
| CN-108441902-B | Monovalent gold cyanide-free gold-plating electroplating solution based on alkaloid composite coordination and application thereof | 厦门大学 | 2020-01-24 | — | — | CN | claimed |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | claimed |
| EP-3275859-A1 | GLAUCOCALYXIN A DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF | Suzhou Pharmavan Cancer Research Center Co., Ltd. (CN) | 2018-01-31 | — | — | EP | claimed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | claimed |
| EP-0538194-B1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA GEIGY AG (CH) | 1997-06-04 | — | — | EP | claimed |
| EP-0540686-B1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1995-08-30 | — | — | EP | claimed |
| US-5319080-A | Antiviral agents | CIBA-GEIGY CORPORATION (US) | 1994-06-07 | — | — | US | claimed |
| EP-0540686-A4 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1993-05-26 | — | — | EP | claimed |
| EP-0540686-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES. | US COMMERCE (US) | 1993-05-12 | — | — | EP | claimed |
| EP-0538194-A1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | claimed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | claimed |
| EP-0394346-A4 | PYRIMIDINE AND PURINE 1,2-BUTADIENE-4-OLS AS ANTI-RETROVIRAL AGENTS | US HEALTH (US) | 1991-12-11 | — | — | EP | claimed |
| EP-0394346-A1 | PYRIMIDINE AND PURINE 1,2-BUTADIENE-4-OLS AS ANTI-RETROVIRAL AGENTS | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1990-10-31 | — | — | EP | claimed |
| WO-1989006235-A1 | PYRIMIDINE AND PURINE 1,2-BUTADIENE-4-OLS AS ANTI-RETROVIRAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-07-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CFTR, ABCB11, SLC26A4 | BRAF 2029/4885PDPK1 3527/4885GDA 2017/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | BRAF 519/4885PDPK1 3297/4885GDA 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.